Dehong Li

Dr. Dehong Li


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
HWHaiyu Wang
Haiyu Wang
YDYumin Ding
Yumin Ding
MZMin Zhuang
Min Zhuang
KLKaixu Li
Kaixu Li
SZShujing Zhao
Shujing Zhao
DLDehong Li
Dehong Li
Gastric cancer, as one of the malignant tumors with a significant disease burden globally, emphasizes the importance of early diagnosis and personalized treatment for improving patient prognosis. In recent years, clinical prediction models (CPMs) have played a crucial role in predicting disease risks, assisting medical decision-making, and evaluating clinical prognosis and benefits as tools for risk–benefit assessment. Nomograms, as an important visualization form of clinical prediction models, have been increasingly applied in tumor-related research. Numerous studies have constructed multiple nomogram models by integrating clinical, pathological, laboratory, imaging data, and genetic characteristics, providing an accurate and effective tool for predicting the risk of gastric cancer, early diagnosis, treatment response assessment, and prognosis analysis. This article aims to review the current clinical applications and research progress of nomograms in gastric cancer, with the goal of providing robust references and theoretical support for clinical practice.

22 January 2025 in Biomarkers in Medicine
Verified
Journal Article
Closed access
FLFugui Lin
Fugui Lin
LYLi Yan
Li Yan
XYXiumei Yuan
Xiumei Yuan
XYXingwen Yang
Xingwen Yang
XYXiaoyan Yang
Xiaoyan Yang
DLDehong Li
Dehong Li
Raftlin (raft-linking) protein is an essential component of the lipid raft structure and plays a crucial role in B and T cell signaling pathways. It facilitates B cell receptor (BCR) signaling by promoting calcium mobilization and tyrosine phosphorylation in the cells while colocalizing with BCR on the cell membrane. Interestingly, Raftlin is internalized in lipopolysaccharide-stimulated T cells by colocalization with Toll-like receptor 4 (TLR4), wherein it exerts a similar role as in B cells. The protein also effectuates poly(I:C) internalization into TLR3-positive endosomes in dendritic and epithelial cells through clathrin binding, thereby affecting interferon-β production. In addition, Raftlin controls the vascular endothelial cells and participates in cell growth and proliferation. Recent studies have indicated Raftlin to be a novel biomarker for the diagnosis due to its upregulated expression in malignant diseases. In this integrated study, we present the biological functions of Raftlin and its expression to provide a theoretical basis for the prevention, diagnosis, and treatment of various diseases.

29 November 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
HWHaiyu Wang
Haiyu Wang
YDYumin Ding
Yumin Ding
SZShujing Zhao
Shujing Zhao
KLKaixu Li
Kaixu Li
DLDehong Li
Dehong Li
Purpose: Identifying high-risk populations and diagnosing gastric cancer (GC) early remains challenging. This study aimed to establish and verify a nomogram model for the early diagnosis of GC based on conventional laboratory indicators.Methods: We performed a retrospective analysis of the clinical data of 2,770 individuals with first diagnosis of GC and 1,513 patients with benign gastric disease from January 2018 to December 2022. The cases were divided into the training set and validation set randomly, with a ratio of 7:3. Variable screening was performed by least absolute shrinkage and selection operator (LASSO) and logistic regression analysis. A nomogram was constructed in the training set to assist in the early diagnosis of GC.Results: There were 4283 patients included in the study, with 2998 patients assigned in the training set and 1285 patients in the validation set. Through LASSO regression and logistic regression analysis, independent variables associated with GC were identified, including CEA, CA199, LYM, HGB, MCH, MCHC, PLT, ALB, TG, HDL, and AFR. The nomogram model was constructed using the above 11 independent indicators. The AUC was 0.803 for the training set and 0.797 for the validation set, indicating that the model showed high clinical diagnostic efficacy. The calibration curves and decision curve analysis (DCA) of the nomogram presented good calibration and clinical application ability.Conclusion: Based on the analysis of large sample size, we constructed a nomogram model with 11 routine laboratory indicators, which showed good discrimination ability and calibration.

1 February 2026 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YDYumin Ding
Yumin Ding
HWHaiyu Wang
Haiyu Wang
KLKaixu Li
Kaixu Li
SZShujing Zhao
Shujing Zhao
DLDehong Li
Dehong Li
Objective: Early diagnosis of central nervous system (CNS) infections remains challenging. The aim of this study was to explore and identify potential biomarkers of CNS infection by comparing cerebrospinal fluid (CSF) proteomic characteristics in patients with tuberculous meningitis (TBM), purulent meningitis (PM), and viral meningitis (VM), as well as in patients without CNS infections. Methods: We conducted the first systematic 4D-DIA comparative proteomic analysis of CSF across TBM (N=6), PM (N=6), VM (N=12), and controls (N=12) using pooled samples. Differential proteins were identified, subjected to GO and KEGG enrichment analyses, and used to construct protein-protein interaction networks for hub protein identification. Results: Proteomic analysis revealed significant differences in CSF protein expression profiles among three types of meningitis. In TBM patients, 53 specific proteins were identified, primarily involved in the complement and coagulation cascade as well as the COVID-19-related immune pathway. PPI network analysis highlighted FGA, FGB, C4BPA, and ADAMTS13 as hub proteins exhibiting notably significant expression levels in TBM patients. In PM patients, 9 proteins were identified, predominantly linked to phagosomes and B-cell receptor signaling, with COLEC11 and ESM1 showing significantly higher expression. In VM patients, 29 proteins were identified, mainly associated with complement and coagulation pathways, featuring higher levels of TMED7, MMP17, and CD81. Conclusion: This study delineated the CSF protein profiles in patients with TBM, PM, VM, and non-CNS infections. We identified several potential biomarkers, including FGA, FGB, C4BPA, ADAMTS13, COLEC11, ESM1, TMED7, MMP17, and CD81. Additionally, we proposed hypothetical molecular mechanisms that may offer valuable diagnostic and therapeutic insights for CNS infections. Nonetheless, given that this is a preliminary exploratory study, further validation through multicenter, large-sample cohort studies and functional experiments is necessary to substantiate the clinical relevance and utility of these biomarkers prior to any potential application in clinical practice.

1 June 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
SZShujing Zhao
Shujing Zhao
KLKaixu Li
Kaixu Li
HWHaiyu Wang
Haiyu Wang
YDYumin Ding
Yumin Ding
DLDehong Li
Dehong Li
Background and Objective: Carbohydrate antigens (CAs) are of great significance in various aspects of gastric cancer (GC). As new members of the family of CAs continue to be discovered, there is a growing focus on their role as therapeutic targets. The comprehensive review aims to provide an in-depth analysis of the current and evolving utilization of CAs in GC, offering valuable insights on the role of CAs as therapeutic targets or biomarkers for GC patients. Methods: A detailed narrative review of the most recent literature was conducted to assess the current use and advancements of CAs in GC. PubMed database was being examined and the last run was on 8 June 2024. Key Content and Findings: This article traces the discovery and biological properties of CAs and their role in GC clinical practice. CAs not only serve a crucial clinical function in the diagnosis, therapy monitoring, metastatic evaluation, and prognosis of GC, but they also improve biological performance when paired with other biomarkers. New CAs, like truncated O-glycans, gangliosides, globo-series glycan, and Lewis antigens, significantly influence GC progression, metastatic infiltration, and individual susceptibility. Moreover, these antigens exhibit unique potential in GC treatment, offering new approaches and insights for GC treatment. Conclusions: The use of CAs in GC diagnosis, prognosis, monitoring, and targeting therapy is beneficial. With the ongoing advancement of detection methodologies and technologies, challenges related to the sensitivity and specificity of CAs detection are anticipated to be progressively and effectively addressed. This will make its application in GC more widespread and effective.

12 December 2025 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
XXXuan Xi
Xuan Xi
HPHeng Pan
Heng Pan
HYHanying Yuan
Hanying Yuan
JXJia Xu
Jia Xu
SZShujing Zhao
Shujing Zhao
Yan LuYan Lu
Yan Lu
Ankylosing spondylitis (AS) is a chronic autoimmune disease characterised by inflammation, bone destruction and pathological new bone formation in the spine and sacroiliac joints. Macrophages, as central innate immune cells, play a pivotal role in AS pathogenesis through dynamic polarisation into pro-inflammatory M1 and anti-inflammatory M2 phenotypes. M1 macrophages dominate early disease stages, producing cytokines such as TNF-α, IL-6 and IL-1β, activating Th1/Th17 responses, and driving tissue inflammation and osteoclast-mediated bone loss.M2 macrophages prevail in later stages, secreting IL-10 and TGF-β, promoting tissue repair, angiogenesis, and ectopic bone formation, contributing to spinal ankylosis. Their plasticity is regulated by cytokine and chemokine signalling, metabolic reprogramming, genetic variants and epigenetic modifications including RNA methylation, non-coding RNAs, and histone modifications. Targeting these pathways offers promising strategies to rebalance macrophage phenotypes, reduce inflammation and prevent structural damage.This review highlights macrophages as central drivers of AS progression and discusses emerging therapeutic approaches that exploit their regulatory mechanisms for precision treatment.